🇺🇸 SGLT-2 inhibitor in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Altered State Of Consciousness — 1 report (50%)
- Ketoacidosis — 1 report (50%)
Other Diabetes approved in United States
Frequently asked questions
Is SGLT-2 inhibitor approved in United States?
SGLT-2 inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SGLT-2 inhibitor in United States?
Peking University People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.